Status:
COMPLETED
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo f...
Eligibility Criteria
Inclusion
- Male or females
- Age at least 55 years or older
- Mild-to-moderate Alzheimer's Disease, with Mini Mental State Examination (MMSE) between 18 and 26, inclusive, Modified Hachinski Ischemic Scale (MHIS) score =/\<4, Global CDR score of 1 or 2, and who have a reliable informant/caregiver to accompany patient to all clinic visits
- If using symptomatic Alzheimer's Disease treatments, patients must be on the medication for 3 months and on a STABLE DOSE for at least 2 months
Exclusion
- Patients cannot be living in a skilled nursing facility
- Patients cannot have poorly-controlled hypertension
- Patients cannot have the following conditions within 6 months of screening: significant cardiovascular disorders, active major depressive disorder, gastroesophageal reflux disease (GERD), or clinically significant sleep disorder
- Various concomitant therapy restrictions
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT00420420
Start Date
November 1 2006
End Date
August 1 2008
Last Update
February 12 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.